Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 1023-1028

  Avigad, Smadar ^a,b   Shukla, Shruti ^a   Naumov, Inna ^a   Cohen, Ian J ^a,b   Ash, Shifra ^a,b   Meller, Isaac ^a   Kollender, Yehuda ^a   Issakov, Josephine ^a   Yaniv, Isaac ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Ewing sarcoma; Methylation; Methylation specific PCR; Progression; RASSF1A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CELL CULTURE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; SAMPLE; TUMOR NECROSIS;

CELL LINE, TUMOR; CHILD; DNA METHYLATION; GENE SILENCING; HUMANS; SARCOMA, EWING'S; TUMOR SUPPRESSOR PROTEINS;

EID: 71049148523     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22115     Document Type: Article

References (48)

1. Avigad S, Yaniv I. Novel approaches for the management of patients with Ewing sarcoma. Future Oncol 2006;2:659-665. (Pubitemid 44575650)
2. Marec-Bérard P, Philip T. Ewing sarcoma: The pediatrician's point of view. Pediatr Blood Cancer 2004;42:477-480. (Pubitemid 38524482)
3. Khoury JD. Ewing sarcoma family of tumors. Adv Anat Pathol 2005;12:212-220.
4. Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer - The application of DNA methylation markers. J Appl Genet 2006;47:365-375. (Pubitemid 44893733)
5. Lu Q, Qiu X, Hu N, et al. Epigenetics, disease, and therapeutic interventions. Ageing Res Rev 2006;5:449-467.
6. Bar-Sela G, Jacobs KM, Gius D. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells. Cancer J 2007;13:65-69.
7. Issa JP. DNA hypermethylation as a therapeutic target in cancer. Clin Cancer Res 2007;13:1634-1637. (Pubitemid 46952927)
8. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007;1776:58-85. (Pubitemid 47332074)
9. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-319. (Pubitemid 30437320)
10. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007;120:3163-3172.
11. Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry 2005;70:576-583. (Pubitemid 40920802)
12. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497-3508. (Pubitemid 40616319)
13. Dammann R, Schagdarsurengin U, Seidel C, et al. The tumor suppressor RASSF1A in human carcinogenesis: An update. Histol Histopathol 2005;20:645-663. (Pubitemid 40468282)
14. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methyl-cytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-1831.
15. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826. (Pubitemid 26296693)
16. Schagdarsurengin U, Wilkens L, Steinemann D, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003;22:1866-1871. (Pubitemid 36513145)
17. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-699. (Pubitemid 32492810)
18. Yang Q, Zage P, Kagan D, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuro-blastoma. Clin Cancer Res 2004;10:8493-8500. (Pubitemid 40053415)
19. Lo PH, Xie D, Chan KC, et al. Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage. Cancer Lett 2007;257:199-205. (Pubitemid 47538825)
20. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter hypermethylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002;21:4345-4349. (Pubitemid 34753843)
21. Astuti D, Agathanggelou A, Honorio S, et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 2001;20:7573-7577. (Pubitemid 33086917)
22. Wong IH, Chan J, Wong J, et al. Ubiquitous aberrant RASSF1A promoter hypermethylation in childhood neoplasia. Clin Cancer Res 2004;10:994-1002. (Pubitemid 38198901)
23. Fulda S, Kufer MU, Meyer E, et al. Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-5877. (Pubitemid 32937956)
24. Lopez-Guerrero JA, Pellin A, Noguera R, et al. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 2001;81:803-814. (Pubitemid 32553402)
25. Tsuchiya T, Sekine K, Hinohara S, et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000;120:91-98.
26. Rathi A, Virmani AK, Harada K, et al. Aberrant hypermethylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms. Clin Cancer Res 2003;9:3674-3678. (Pubitemid 37169234)
27. Pallarés J, Velasco A, Eritja N, et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 2008;21:691-699. (Pubitemid 351744834)
28. Li Y, Wei Q, Cao F, et al. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women. Oncol Rep 2008;19:1149-1153.
29. Hu J, Li H, Shi T, et al. Relationship between the expression of RASSF1A protein and promoter hypermethylation of RASSF1A gene in bladder tumor. J Huazhong Univ Sci Technolog Med Sci 2008;28:182-184.
30. Kee SK, Lee JY, Kim MJ, et al. Hypermethylation of the Ras association domain family 1A (RASSF1A) gene in gallbladder cancer. Mol Cells 2007;24:364-371.
31. Ye M, Xia B, Guo Q, et al. Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China. BMC Cancer 2007;7:120. (Pubitemid 47162435)
32. Qian ZR, Sano T, Yoshimoto K, et al. Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 2005;85:464-473. (Pubitemid 40523939)
33. Gao Y, Guan M, Su B, et al. Hypermethylation of the RASSF1A gene in gliomas. Clin Chim Acta 2004;349:173-179.
34. Whitehurst AW, Ram R, Shivakumar L, et al. The RASSF1A tumor suppressor restrains anaphase-promoting complex/cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cells. Mol Cell Biol 2008;28: 3190-3197. (Pubitemid 351657084)
35. Ohali A, Avigad S, Zaizov R, et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004;23:8997-9006. (Pubitemid 39657791)
36. Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: A perspective. Oncogene 2005;24: 2909-2915. (Pubitemid 40638099)
37. Cheng T. Cell cycle inhibitors in normal and tumor stem cells. Oncogene 2004;23:7256-7266. (Pubitemid 39382159)
38. Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006;24:13-19.
39. Feng W, Shen L, Wen S, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007;9:R57. (Pubitemid 350187466)
40. Michalowski MB, de Fraipont F, Plantaz D, et al. Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 2008;50:29-32. (Pubitemid 350234261)
41. Banelli B, Gelvi I, Di Vinci A, et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005;24:5619-5628. (Pubitemid 43119355)
42. Sugawara W, Haruta M, Sasaki F, et al. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 2007;49: 240-249. (Pubitemid 47236211)
43. Safar AM, Spencer H III, Su X, et al. Methylation profiling of archived non-small cell lung cancer: A promising prognostic system. Clin Cancer Res 2005;11:4400-4405. (Pubitemid 40825630)
44. Lee JS, Lo PK, Fackler MJ, et al. A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women. Cancer Biol Ther 2007;6:1114-1120.
45. Shaw RJ, Hall GL, Lowe D, et al. CpG island methylation phenotype (CIMP) in oral cancer: Associated with a marked inflammatory response and less aggressive tumour biology. Oral Oncol 2007;43:878-886. (Pubitemid 47369250)
46. Hamilton JP, Sato F, Greenwald BD, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 2006;4:701-708. (Pubitemid 43825806)
47. Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des 2007;13:2584-2620. (Pubitemid 47430437)
48. Fiegl H, Elmasry K. Cancer diagnosis, risk assessment and prediction of therapeutic response by means of DNA hypermethylation markers. Dis Markers 2007;23:89-96. (Pubitemid 46333638)